ArticleEye (London, England)2024

Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study.

Daniel S Pereira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.